YMAB

Y-mAbs Therapeutics Inc.

Price

return (12m)

p/e

-20.98

p/bv

4.43

DIVIDEND YIELD

0.00%

YMAB price

Y-mAbs Therapeutics

If you had invested

exposure

years ago

ago, you would now have *

today you would have:

*The amount considers the reinvestment of dividends.

Return on Investment YMAB

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

0.00%

3 months

0.00%

1 year

0.00%

2 years

0.00%

5 years

0.00%

10 years

0.00%

Profitability Comparator

If you had invested

years ago

today you would have:

Fundamentals YMAB

Valuation

P/E

-20.98

Sector -3.16

Industry -3.16

P/BV

4.43

Sector 1.80

Industry 1.80

P/Revenue (PSR)

4.48

Sector 2.05

Industry 2.05

EV/EBITDA

-13.90

Sector -210.13

Industry -210.13

EV/EBIT

-13.73

Sector -36.38

Industry -36.38

P/EBITDA

-16.56

Sector -19.73

Industry -19.73

P/EBIT

-16.36

Sector -67.09

Industry -67.09

P/Total Assets

3.31

Sector 1.06

Industry 1.06

P/Net Current Assets

6.24

Sector -9.56

Industry -9.56

P/Working Capital

5.63

Sector -93.54

Industry -93.54

EPS

-0.41

Sector -1.78

Industry -1.78

BVPS

1.94

Sector 1.99

Industry 1.99

Efficiency

Gross Margin

81.29%

Sector 41.27%

Industry 41.27%

EBITDA Margin

-28.43%

Sector -21,198.78%

Industry -21,198.78%

EBIT Margin

-27.39%

Sector -35.28%

Industry -35.28%

Net Profit Margins

-21.37%

Sector -35.71%

Industry -35.71%

Asset Turnover

0.17

Sector 0.03

Industry 0.03

Profitability

ROE

-21.11%

Sector -61.33%

Industry -61.33%

ROA

-15.76%

Sector -54.29%

Industry -54.29%

ROIC

-61.43%

Sector -1,801.33%

Industry -1,801.33%

Dividends

Dividend yield

0.00%

Sector -

Industry -

Payout

Sector -

Industry -

Debt

Current Ratio

4.00

Sector 2.91

Industry 2.91

Net Debt / EBITDA

2.66

Sector -20.88

Industry -20.88

Net Debt / EBIT

2.63

Sector -3.40

Industry -3.40

Net Debt / Equity

-0.71

Sector -34,305.41

Industry -34,305.41

Gross Debt / Equity

0.00

Sector -0.81

Industry -0.81

Equity/Assets

0.75

Sector 0.46

Industry 0.46

Liabilities/Assets

0.25

Sector 0.41

Industry 0.41

Growth

5Y Revenue CAGR

17.57%

Sector -

Industry -

5Y Earnings CAGR

-30.94%

Sector -

Industry -

Fundamentals YMAB

DRAG THE FRAME TO SEE MORE DATA

Assets	Price ($)	Return 12m	DY	P/E	P/BV	ROE	Net Profit Margins
YMAB Y-mAbs Therapeutics Inc.	$0.00	-	0.00%	-20.98	4.43	-21.11%	-21.37%
PFE Pfizer Inc.	$29.34	29.45%	5.59%	43.90	1.99	4.43%	6.34%
ABBV AbbVie Inc.	$289.47	37.80%	2.31%	53.66	0.00	-%	14.76%
NVO Novo Nordisk A/S	$40.24	-9.17%	4.66%	9.73	5.17	60.28%	35.32%
MRK Merck & Co. Inc.	$146.62	78.84%	2.26%	151.28	8.26	5.07%	3.64%
AZN AstraZeneca PLC	$185.93	12.89%	1.71%	25.01	5.71	24.18%	18.97%
GILD Gilead Sciences Inc.	$167.61	40.09%	1.94%	45.45	16.08	26.68%	14.89%
BMY Bristol-Myers Squibb Company	$62.45	40.35%	5.06%	13.78	5.44	44.06%	18.47%
ZTS Zoetis Inc.	$79.97	-32.35%	2.60%	12.71	10.64	64.91%	27.69%
AMGN Amgen Inc.	$461.90	49.19%	2.13%	28.86	21.58	91.47%	22.95%
REGN Regeneron Pharmaceuticals Inc.	$898.12	39.39%	0.41%	21.68	2.96	14.04%	27.86%
HALO Halozyme Therapeutics Inc.	$104.69	53.28%	0.00%	37.10	106.90	173.67%	24.86%
MCK McKesson Corporation	$1,056.55	25.75%	0.34%	25.96	-30.85	-168.45%	1.12%
VRTX Vertex Pharmaceuticals Incorporated	$546.20	30.98%	0.00%	34.82	6.62	20.80%	30.61%
CAH Cardinal Health Inc.	$266.52	36.72%	0.81%	34.74	-21.86	-63.98%	0.67%
ARGX argenx SE	$903.39	8.53%	0.00%	13.26	-	-%	25.42%
HRMY Harmony Biosciences Holdings Inc.	$33.09	5.55%	0.00%	12.39	2.25	20.46%	18.88%

Stock vs Indice Comparison Tool

If you had invested

years ago

ago, you would now have *

today you would have:

*This calculation reflects price variation only.

YMAB - Historical Dividends

no dividend paid in the period.

Current Dividend Yield

0.00%

5-year average Dividend Yield

0.00%

Current Payout

—

5-year average Payout

—

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

Average Investor10 user rating

4.0 (0 people)

United States

11 years

Founded: 2015

2018

Time since IPO - 8 years

104

Employees

Y-mAbs Therapeutics Inc. (United States) is listed on the Nasdaq and has a market capitalization of $387.45 million, with shareholders equity totaling $87.49 million.

The company employs approximately 104 people and operates in the Health Care sector, within the Biotechnology industry.

Over the past 12 months, Y-mAbs Therapeutics Inc. reported $86.44 million in revenue, generating net income of $-18.47 million.

Key financial metrics include a P/E ratio of -20.98, a price-to-book (P/B) ratio of 4.43, and a trailing twelve-month dividend yield of 0.00%.

The company trades under the ticker YMAB.

Market cap

$387.45 million

Net worth

$87.49 million

$87,490,000.00

Assets

$117.21 million

$117,210,000.00

Total Shares Outstanding

45.00 million

45,000,000

Average Daily Trading Volume

$1.07 million

$1,065,291.50

Sector

Health Care

Industry

Biotechnology

YMAB

YMAB revenue and profits

Financial Results YMAB

DRAG THE FRAME TO SEE MORE DATA

YMAB cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more assets

BFRA - Biofrontera

$- -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/BV

0.00

MCK - McKesson

$1,056.55 23,65% (12M)

P/E

25.96

0.34%

ROE

-168.45%

P/BV

-30.85

CAH - Cardinal Health

$266.52 35,89% (12M)

P/E

34.74

0.81%

ROE

-63.98%

P/BV

-21.86

MRK - Merck & Co.

$146.62 75,94% (12M)

P/E

151.28

2.26%

ROE

5.07%

P/BV

8.26

ABBV - AbbVie

$289.47 36,37% (12M)

P/E

53.66

2.31%

ROE

P/BV

0.00

PFE - Pfizer

$29.34 28,20% (12M)

P/E

43.90

5.59%

ROE

4.43%

P/BV

1.99

AZN - AstraZeneca

$185.93 11,81% (12M)

P/E

25.01

1.71%

ROE

24.18%

P/BV

5.71

BMY - Bristol-Myers Squibb

$62.45 39,87% (12M)

P/E

13.78

5.06%

ROE

44.06%

P/BV

5.44

BFRA - Biofrontera

$- -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$1,056.55 23,65% (12 M)

P/L

25.96

0.34%

ROE

-168.45%

P/VP

-30.85

CAH - Cardinal Health

$266.52 35,89% (12 M)

P/L

34.74

0.81%

ROE

-63.98%

P/VP

-21.86

MRK - Merck & Co.

$146.62 75,94% (12 M)

P/L

151.28

2.26%

ROE

5.07%

P/VP

8.26

ABBV - AbbVie

$289.47 36,37% (12 M)

P/L

53.66

2.31%

ROE

P/VP

0.00

PFE - Pfizer

$29.34 28,20% (12 M)

P/L

43.90

5.59%

ROE

4.43%

P/VP

1.99

AZN - AstraZeneca

$185.93 11,81% (12 M)

P/L

25.01

1.71%

ROE

24.18%

P/VP

5.71

BMY - Bristol-Myers Squibb

$62.45 39,87% (12 M)

P/L

13.78

5.06%

ROE

44.06%

P/VP

5.44

Frequently Asked Questions

What is the price of Y-mAbs Therapeutics (YMAB) today?

The current price of Y-mAbs Therapeutics (YMAB) is $0.00. The stock began the year trading around $0.00 and is currently priced at $0.00. You can follow the real-time price chart, review historical performance, and track broader market trends directly on the platform.

When does Y-mAbs Therapeutics (YMAB) pay dividends?

Y-mAbs Therapeutics (YMAB) did not pay dividends over the past year.

Is Y-mAbs Therapeutics (YMAB) a good investment?

Y-mAbs Therapeutics (YMAB) is currently trading at $0.00 with a P/E ratio of -20.98. This represents a -1,099% premium compared to its historical average P/E. Over the past year, the stock paid $0.00 in dividends, resulting in a dividend yield of 0.00%. The total shareholder return over the same period was 0.00%.

Investors should keep in mind that past performance does not guarantee future results. This information is provided for educational purposes only and should not be considered investment advice.

How can I buy Y-mAbs Therapeutics (YMAB) stock?

You can buy Y-mAbs Therapeutics (YMAB) shares through any brokerage account that provides access to U.S. stock exchanges. After opening and funding your account, simply search for the ticker symbol YMAB and place a buy order. Before investing, consider factors such as your financial goals, risk tolerance, and overall portfolio allocation.

How much would 100 shares of Y-mAbs Therapeutics (YMAB) yield today?

Over the past month, Y-mAbs Therapeutics (YMAB) has returned 0.00% — 0.00% over the past year, and 0.00% over the past five years, including price appreciation and dividends.

In the last 12 months, the company paid a total of 0.00 per share in dividends, resulting in a dividend yield of 0.00%.

If you were to purchase 100 shares of Y-mAbs Therapeutics (YMAB) today at the current price of $0.00 your total investment would be $0.00.

Based on historical performance, the investment would have grown to approximately:

$0.00 after 1 year
$0.00 after 5 years
$0.00 after 10 years

Past performance does not guarantee future results. This content is for informational purposes only and should not be considered investment advice.

YMAB

Y-mAbs Therapeutics Inc.

Price

return (12m)

p/e

p/bv

DIVIDEND YIELD

Return on Investment YMAB

Target price created!

Delete target price?

Your Target Price strategy deserves unlimited alerts

Valuation

Efficiency

Profitability

Dividends

Debt

Growth

COMPARING YMAB WITH OTHER STOCKS

ABOUT Y-mAbs Therapeutics

Y-mAbs Therapeutics Inc.

United States

11 years

2018

104

PROFIT X PRICE YMAB

Financial Results YMAB

YMAB cash flow

Asset, Revenue and Profit Growth - YMAB

YMAB balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

MRK - Merck & Co.

ABBV - AbbVie

PFE - Pfizer

AZN - AstraZeneca

BMY - Bristol-Myers Squibb

Frequently Asked Questions